Accendra Health ACH 深 沪
等待开盘 10-14 09:30:00 美东时间
0.3151
-0.075
-19.31%
华盛通- 最 高0.3932
- 今 开0.3932
- 成交量 227.81万股
- 最 低 0.3151
- 昨 收 0.3905
- 总市值 2423.27万
- 52周最高 5.60
- 市盈率 静 --
- 换手率 2.96%
- 52周最低 0.3151
- 委 比 0.00%
- 总股本 7690.47万
- 历史最高 49.1525
- 量 比 1.61
- 振 幅 20.00%
- 历史最低 0.3151
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Accendra Health Addresses NYSE Listing Price Deficiency
Accendra Health ( ($ACH) ) has provided an announcement. On October 6, 2026, Ac...
10-10 04:28
Accendra Health receives NYSE notice
Accendra Health (ACH) said on Friday it received a notice from the NYSE after its average closing share price fell below $1 for 30 consecutive trading days. The company plans to notify the NYSE of it...
10-10 04:19
Accendra Health names new CEO
Accendra Health (ACH) named board member Kenneth Gardner-Smith as its next president and CEO, with the appointment expected to take effect early in Q4 2026. Gardner-Smith will succeed Edward A. Pesick...
09-17 18:54
Accendra Health Names Kenneth Gardner-Smith as Next President and CEO; Expected To Assume the Role Early in Q4 of 2026, succeeding Edward Pesicka
Chief Commercial Officer Accendra Health also today named Scott Lloyd to the role of Chief Commercial Officer, effective October 5, 2026. The Company created the position to bring commercial strategy, sales, and provider and payor partnerships under a single leader, simplifying the commercial struct...
09-17 18:34
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5
Citigroup analyst Daniel Grosslight downgrades Accendra Health (NYSE:ACH) from Buy to Neutral and lowers the price target from $4.5 to $1.5.
08-11 20:21
Accendra Health Announces CEO Retirement and Succession Plan
Accendra Health ( ($ACH) ) has shared an announcement. On August 10, 2026, Acce...
08-10 18:56
Accendra Health Lowers FY2026 Sales Guidance from $2.550B-$2.650B to $2.450B-$2.550B vs $2.574B Est
Accendra Health (NYSE:ACH) lowers FY2026 sales outlook from $2.550 billion-$2.650 billion to $2.450 billion-$2.550 billion vs $2.574 billion estimate.
08-10 18:46
Accendra Health’s President And CEO Edward Pesicka Plans To Retire By 2026 End
Accendra Health, Inc. (NYSE:ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company’s Boar...
08-10 18:36
Accendra Health 2026财年第二季度财报：营收与调整后EBITDA下滑
Accendra Health 2026财年第二季度营收下降约10.1%至6.132亿美元，而GAAP持续经营业务摊薄每股亏损从1.09美元扩大至1.16美元。调整后EBITDA从9660万美元降至6010万美元，自由现金流转为负2510万美元。尽管因某大型商业支付方退出而进行了成本削减，但该季度毛利依然较低。Accendra Health还削减了3.85亿美元的债务，并更新了2026财年业绩指引，预计营收为24.5亿至25.5亿美元，调整后EBITDA为3亿至3.2亿美元。
08-10 10:56
